Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

[Detection of bone metastases in patients with neuroendocrine gastrointestinal tumors].

Der Radiologe 1999 March
INTRODUCTION: In patients with neuroendocrine gastrointestinal tumors and liver metastases, but without known extrahepatic manifestations, liver transplantation may be indicated as curativ or "long-term-palliativ" therapy. For these patients the absence of bone lesions is mandatory.

METHODS: 4 patients with a histologically proven neuroendocrine tumor were examined in order to exclude further metastases. We compared the diagnostic value of somatostatin-receptor-scintigraphy (SRS), X-ray, 99mTc-DPD-scintigraphy, CT and MRI.

RESULTS: In all 4 patients bone metastases could be detected using SRS, CT und MRT. In one case MRI proved multiple infiltrations, while SRS showed only a solitary, focal lesion. 99mTc-DPD-scintigraphy was positive in 3 cases, X-ray in 1 case.

CONCLUSION: As a diagnostic strategy we initially recommend somatostatin-receptor-scintigraphy. When locating suspect areas in SRS, MRI should be the method of choice for the exact evaluation of malignant bone infiltrations. A CT-guided biopsy is necessary to gain histological information.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app